Loading company…
Shanghai Xingfan Biotechnology develops small-molecule drugs, including oncology treatments.
Founded in 2024 and based in Shanghai, China, Shanghai Xingfan Biotechnology develops differentiated small-molecule drugs with clinical potential, focusing on oncology. In April 2026, it closed a Series A round from Tengyuan Capital, Oriza Holdings and IDG Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in